News & Updates

Show Multimedia Only
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer

Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer

12 Sep 2022

In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.

12 Sep 2022